Replies to post #222733 on Biotech Values

[DewDiligence]

(PTLA)—AMAG acquires (private) Perosphere Pharmaceuticals for $68M cash and contingent payments:

https://globenewswire.com/news-release/2018/12/13/1666492/0/en/AMAG-Pharmaceuticals-Enters-Into-Definitive-Merger-Agreement-to-Acquire-Perosphere-Pharmaceuticals.html

Perosphere has a FXa-inhibitor reversal agent that has completed phase-2b; if approved, it would compete against PTLA’s Andexxa.